Drug-Eluting Balloons

This channel includes news and new technology innovations for drug coated balloons, also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis.

FDA Approves 200, 250 Millimeter In.Pact Admiral Drug Coated Balloons
Technology | Drug-Eluting Balloons | June 15, 2018

June 15, 2018 — Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm...

News | Drug-Eluting Balloons | May 29, 2018

May 29, 2018 – M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus...

The Medtronic In.Pact Admiral Paclitaxel-coated (DCB) Percutaneous Transluminal Angioplasty Balloon Catheter is now indicated for lesions up to 360 mm in length.
Technology | Drug-Eluting Balloons | May 03, 2018

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has expanded the indication for the Medtronic In.Pact ...

In.Pact Admiral Balloon Demonstrates Consistent, Durable Outcomes in LINC 2018 Studies
News | Drug-Eluting Balloons | February 07, 2018

February 7, 2018 — Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral...

The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (...

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | September 18, 2017

September 18, 2017 — Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (...

Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017

September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual...

Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons | September 13, 2017

September 13, 2017 — Medtronic plc announced that the In.Pact Admiral...

Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons | August 29, 2017

August 29, 2017 — C.R. Bard Inc. announced the Lutonix 035...

News | Drug-Eluting Balloons | August 15, 2017

August 15, 2017 — Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food...

Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons | July 26, 2017

July 26, 2017 — The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market...

Philips acquires purchases Spectranetics
Feature | Cardiovascular Business | June 28, 2017

June 28, 2017 — Philips Healthcare...

News | June 12, 2017

June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study...

Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons | April 26, 2017

April 26, 2017 — Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA...

Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch
News | Peripheral Artery Disease (PAD) | March 09, 2017

March 9, 2017 — Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a...

Overlay Init